Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Market Strategies LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 82.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,367 shares of the company's stock after buying an additional 9,652 shares during the period. Capital Market Strategies LLC's holdings in CRISPR Therapeutics were worth $727,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of CRSP. PFG Investments LLC grew its holdings in CRISPR Therapeutics by 9.9% during the 4th quarter. PFG Investments LLC now owns 10,603 shares of the company's stock worth $417,000 after acquiring an additional 952 shares during the last quarter. KBC Group NV grew its holdings in CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock worth $2,382,000 after acquiring an additional 57,696 shares during the last quarter. Perigon Wealth Management LLC grew its holdings in CRISPR Therapeutics by 11.4% during the 4th quarter. Perigon Wealth Management LLC now owns 16,757 shares of the company's stock worth $675,000 after acquiring an additional 1,717 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in CRISPR Therapeutics by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,098 shares of the company's stock worth $712,000 after acquiring an additional 1,717 shares during the last quarter. Finally, Spire Wealth Management grew its holdings in CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after acquiring an additional 1,482 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now owns 6,068 shares in the company, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company's stock, valued at $3,288,822.60. This represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,953 shares of company stock worth $736,087 in the last 90 days. 4.30% of the stock is owned by company insiders.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded up $0.58 during trading hours on Monday, hitting $36.87. The stock had a trading volume of 1,526,546 shares, compared to its average volume of 1,708,921. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $67.88. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -8.45 and a beta of 1.88. The company has a 50 day simple moving average of $36.59 and a two-hundred day simple moving average of $41.39.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter in the prior year, the business earned ($1.43) EPS. The firm's revenue was up 71.6% compared to the same quarter last year. Equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CRSP shares. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their target price for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Stifel Nicolaus lowered their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a report on Thursday, February 13th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target on the stock in a research report on Wednesday, February 12th. Finally, Truist Financial increased their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.